Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (PSTV) announced that Dr. Norman LaFrance will present on their investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), at the Targeted Radiopharmaceuticals Summit in Boston on July 27, 2022. The presentation is titled ‘Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers’, and will provide updates on the U.S. ReSPECT clinical trials. Plus Therapeutics focuses on developing innovative cancer therapies, utilizing advanced nanotechnology for drug delivery.
Plus Therapeutics (PSTV) announced the completion of Cohort 1 enrollment in the ReSPECT-LM Phase 1/2a trial for 186RNL, targeting leptomeningeal metastases. The company achieved key manufacturing objectives and presented positive interim data on 186RNL for glioblastoma. Financially, cash stood at $18.1 million with a net loss of $5.3 million for Q2 2022. Operating expenses rose to $5.1 million due to CMC development costs. The company plans multiple data presentations and aims to finalize GMP production for ongoing clinical trials by the end of 2022.
Plus Therapeutics, Inc. (PSTV) announced it will report its second quarter 2022 financial results on July 21, 2022, post-market. Following this, management will host a conference call at 5:00 p.m. ET to discuss results and provide corporate updates. A live webcast will be available, and participants can pre-register for the call. Plus Therapeutics focuses on innovative, targeted radiotherapeutics for tough cancers, employing proprietary nanotechnology for enhanced drug delivery.
Plus Therapeutics (PSTV) has successfully completed technology transfer and initiated cGMP manufacturing of its Rhenium-186 NanoLiposome (186RNL) drug intermediate with Piramal Pharma Solutions. This milestone supports ongoing clinical trials for rare cancers. The 186RNL product is currently undergoing stability testing and adheres to FDA guidelines. The company is on track to provide GMP drug availability in late 2022 for trials focusing on recurrent glioblastoma and leptomeningeal metastases. Feedback from recent FDA meetings will guide future clinical development plans.
Plus Therapeutics (PSTV) has entered a multi-year agreement with Biocept to utilize the CNSide assay in its ReSPECT-LM clinical trial, aiming to treat patients with leptomeningeal metastasis. This assay will help monitor tumor cell burden in cerebrospinal fluid (CSF) and evaluate treatment response, enhancing the effectiveness of Rhenium-186 NanoLiposome (186RNL). CNSide offers advanced detection and quantification of tumor cells, significantly benefiting the clinical trial's patient management and treatment assessment.
Plus Therapeutics (PSTV) announced the successful completion of enrollment for the first cohort in its ReSPECT-LM Phase 1/2a clinical trial of Rhenium-186 NanoLiposome (186RNL) targeting leptomeningeal metastases. Initial results show no dose limiting toxicities, indicating promising drug performance. The next step involves the Data Safety & Monitoring Board evaluating further dose escalation. The investigational drug aims to provide a safer, effective treatment for this rare cancer complication, which has a dismal survival rate. Plus Therapeutics expects to release further updates in Q3 2022.
Plus Therapeutics (PSTV) announced promising interim results from its Phase 1/2a ReSPECT-GBM trial for Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma patients. The study showed that 186RNL, delivered via convection enhanced delivery, effectively targets tumors with minimal radiation exposure to healthy tissue. No significant adverse events were recorded during dose escalation, which involved 24 patients across seven cohorts. The company plans to initiate a Phase 2 trial by the end of 2022 and is also evaluating 186RNL for additional indications.
Plus Therapeutics, Inc. (Nasdaq: PSTV) is set to present virtually at the 2022 H.C. Wainwright Global Investment Conference from May 23-26, 2022. Marc Hedrick, M.D., President and CEO, will lead the presentation, available on-demand during the conference and archived for 90 days on the company’s website. Plus Therapeutics focuses on innovative cancer treatments through advanced radiotherapeutics and liposomal encapsulation technology. Interested investors can arrange virtual meetings with the company's management through the conference coordinator.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at the 2022 Q2 Investor Summit on May 3, 2022, at 12:30 p.m. ET in New York. The company develops targeted radiotherapeutics for hard-to-treat cancers. Interested investors can arrange meetings with management at the event. A webcast of the presentation will be available on the Plus Therapeutics website, with a replay accessible for 90 days afterward. Plus Therapeutics focuses on innovative cancer treatments using a proprietary nanotechnology platform.
Plus Therapeutics (PSTV) announced the first patient dosing in the ReSPECT-LM Phase 1/2a trial of 186RNL for leptomeningeal metastases, highlighting a significant step in its drug development efforts. The company reported a cash balance of $21.2 million as of March 31, 2022, reflecting an increase from $18.4 million at year-end 2021. However, total operating expenses rose to $3.9 million, leading to a net loss of $4.1 million, or $(0.19) per share, for Q1 2022. Plus Therapeutics also expanded its partnership with Medidata to enhance trial efficiency, aiming for FDA approval for multiple upcoming trials.